American College of Clinical Pharmacy
      Search      Cart
         

Critical Care PRN Focus Session -- Anticoagulation Controversies in the ICU

Saturday, October 26, 2019 from 1:45 PM to 3:15 PM EST at 2nd Floor: Sutton Center/South

Available for 1.50 hours of CPE credit
Activity Number: 0217-0000-19-173-L01-P
Activity Type: An Application-Based Activity


Speakers
  • Moderator: Komal Pandya, B.Pharm.

Are DOACs Novel Enough to Treat HIT?
1:45 PM

Speakers
  • Kevin R. Donahue, Pharm.D., BCPSSpeaker: Kevin R. Donahue, Pharm.D., BCPS
    Clinical Pharmacy Specialist: Cardiac Critical Care Houston Methodist Hospital
      View Biography


Learning Objectives
1. Summarize evidence for use of DOACs for patients with confirmed HIT.
2. Identify critically ill patients appropriate for treatment of HIT with a DOAC.
3. Given a patient-specific scenario, design an appropriate DOAC regimen.
Avoiding Clots in a Crisis-Balancing Anticoagulation in ECMO
2:15 PM

Speakers

Learning Objectives
1. Evaluate the utility of using coagulation assays for monitoring patients on ECMO.
2. Define the optimal anticoagulation goal for patients on ECMO.
3. Discuss the risks and benefits of different anticoagulation options in patients undergoing ECMO.
To Lyse or Not to Lyse: Thrombolytic Strategies in Acute Pulmonary Embolism
2:45 PM

Speakers
  • Tyree H. Kiser, Tyree H. Kiser, Pharm.D., FCCP, BCPSSpeaker: Tyree H. Kiser, Tyree H. Kiser, Pharm.D., FCCP, BCPS
    Professor, University of Colorado Anschutz Medical Campus, Skaggs School of Pharmacy & Pharmaceutical Sciences, Aurora, Colorado
      View Biography


Learning Objectives
1. Evaluate the evidence for use of thrombolytic therapy in patients with intermediate-risk pulmonary embolism.
2. Select and recommend an appropriate dosing strategy for thrombolytic use in patients with pulmonary embolism.